Amgen Stock Price Analysis: Current Valuation and 52-Week Performance Overview
As of the last available data, Amgen’s stock price was $288.23 USD, with a 52-week high of $339.17 and a 52-week low of $253.30.
One minute to read
Amgen Inc
Amgen Poised for Q2 Earnings Amid Rare Disease Expansion and Market Optimism
Amgen is set to report its Q2 earnings, with investors eagerly awaiting updates on its expansion into the rare disease market and its quarterly dividend payout.
2 minutes to read
Amgen Reaffirms Dividend, Demonstrating Commitment to Shareholders Amid Market Volatility
Amgen reaffirms its quarterly dividend at $2.38 per share, demonstrating its commitment to delivering value to investors despite market fluctuations.
2 minutes to read
Amgen Announces Dividend and Q2 Results Amid Market Volatility
Amgen Inc. has announced a third quarter dividend and will report its second quarter financial results, despite market volatility, with its focus on innovative medicines and patient outcomes driving long-term growth prospects.
2 minutes to read
Amgen Set to Release Q2 Financials Amid Market Challenges and Growth Opportunities in Biotech
Amgen is set to release its second quarter financial results on August 5, 2025, amidst market leading artists, and the theme parkour Street characters. 2 Date: 2025/07-07T00:55:00.000Z Source: www.finanews.com
Sands China’s shares price-Part of Ex…
2 minutes to read
Amgen Inc. Shows Market Resilience with Stable Stock Amid Biotech Challenges
Amgen Inc. has demonstrated resilience in a challenging market, driven by its commitment to innovative medicines and strong market presence, positioning it for continued growth and success.
2 minutes to read
Amgen Inc. Announces Promising Phase 2 Results for MariTide, Boosting Investor Confidence
Amgen Inc. has made significant strides in research and development, unveiling promising results for its MariTide treatment and solidifying its position as a leader in the biotechnology industry.
2 minutes to read
Amgen Inc. Stock Soars on Successful Gastric Cancer Trial Results
Amgen Inc.’s stock price has surged due to positive news from its clinical trials, particularly the Phase 3 FORTITUDE-101 trial, which demonstrated the effectiveness of bemarituzumab in treating gastric cancer.
2 minutes to read
Amgen’s MariTide Study Shows Promising Weight Loss Results Despite Initial Stock Dip
Amgen’s experimental weight-loss drug MariTide has yielded promising results in a phase 2 study, with patients achieving significant weight loss without plateauing, despite a temporary dip in the company’s share price.
2 minutes to read
Amgen Highlights Strategic Vision at Goldman Sachs Conference Amid Dow Jones Uptrend
Amgen’s presentation at the Goldman Sachs conference comes as the broader market experiences a welcome uptrend, with the Dow Jones index rising 0.964% since the start of 2025.
2 minutes to read